Francesco de Rubertis, Director at Centessa Pharmaceuticals plc (CNTA), bought 192,048 shares at $12.62 ($2.4M) on 2021-12-01, disclosed to the SEC on 2021-12-02.
Open-market purchase of $2.4M CNTA by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.62 | 855 | $10K | 0.4% |
| 2 | $11.62 | 35,992 | $418K | 17.8% |
| 3 | $11.62 | 35,992 | $418K | 17.8% |
| 4 | $12.62 | 1,399 | $18K | 0.8% |
| 5 | $12.62 | 58,905 | $743K | 31.6% |
| 6 | $12.62 | 58,905 |
| $743K |
| 31.6% |
| Total | $12.24 avg | 192,048 | $2.4M | 100% |
| Filing → |
| CNTA | BUY | 2021-06-04 | $12.0M | — | Filing → |
| NERV | SELL | 2016-08-12 | $10.0M | — | Filing → |
| NERV | BUY | 2015-03-20 | $975K | — | Filing → |